返回
Childhood tuberculosis
DOI:10.1097/QCO.0000000000000866.png)
摘要
En 中文
Purpose of review We discuss the most recent literature to support the identification of children at risk for tuberculosis and optimal testing and treatment strategies. Recent findings The identification and management of children with tuberculosis has increased in complexity due to the recent severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic, greater use of immunosuppressive agents, and the administration of shorter, rifamycin-containing treatment regimens. Advancements in the diagnosis and treatment of tuberculosis in children include: use of interferon gamma release assays (IGRAs); molecular-based tests; and shorter courses of treatment. While the essential steps to identify and treat children at risk for tuberculosis remain unchanged, providers must be aware of impact of these challenges. The SARS-CoV-2 pandemic will likely have a negative impact on global tuberculosis control. It is important that countries maintain a comprehensive approach to the identification and management of children at risk for tuberculosis. Increasing evidence supports enhanced utilization of IGRAs and molecular-based testing to improve the diagnosis of tuberculosis in children. Shorter course, rifamycin-based treatment regimens are available to treat children with tuberculosis infection; however, their use is limited in some immunosuppressed children due to drug-drug interactions.
Keyword:
IGRA
isoniazid
rifapentine
pediatric tuberculosis
tuberculosisinfection
Xpert
期刊
IF:
4
论文数:
2.4K
被引数:
4.2K
机构
引用论文
Automated neurite extraction using dynamic programming for high-throughput screening of neuron-based assays
NeuroImage
IF0
Sensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children
JAMA PEDIATRICS
IF18

